Biovac Signs Deal to Develop and Manufacture Oral Cholera Vaccine for African and Global Markets.

23 NOVEMBER 2022 – South African based Bio-pharmaceutical company, Biovac, has concluded a ground-breaking licensing and technology transfer agreement with the International Vaccine Institute (IVI), a non-profit international organisation headquartered in South Korea, for the manufacture of an oral cholera vaccine (OCV).